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l e t t e r S Hepatitis C virus (HCV) is endemic in many countries due to its high propensity for establishing persistence 1 . The presence of HCV-specific T cells in subjects repeatedly exposed to HCV who test negative for HCV RNA and antibodies and who do not have any history of HCV infection has been interpreted as T cell-mediated protection [2] [3] [4] [5] . Here, we show in nonhuman primates that repeated exposure to human plasma with trace amounts of HCV induced HCV-specific T cells without seroconversion and systemic viremia but did not protect upon subsequent HCV challenge. Rather, HCV-specific recall and de novo T cell responses, as well as intrahepatic T cell recruitment and interferon-g (IFN-g) production, were suppressed upon HCV challenge, concomitant with quantitative and qualitative changes in regulatory T cells (T reg cells) that occurred after subinfectious HCV exposure and increased after HCV challenge. In vitro T reg cell depletion restored HCV-specific T cell responses. Thus, T cells primed by trace amounts of HCV do not generate effective recall responses upon subsequent HCV infection. Subinfectious HCV exposure predisposes to T reg cell expansion, which suppresses effector T cells during subsequent infection. Strategies to reverse this exposure-induced immune suppression should be examined to aid in the development of T cell−based vaccines against HCV and other endemic pathogens.
At least 170 million people worldwide are persistently infected with HCV, a leading cause of chronic liver inflammation, cirrhosis and cancer 1 . Spontaneous HCV clearance occurs in less than 25% of acute infections and is typically associated with T cell rather than antibody responses 1, [6] [7] [8] [9] . HCV-specific T cell responses have also been described in subpopulations of injection drug users who test negative for HCV RNA and antibodies to HCV and do not have past HCV infection despite frequent exposure [2] [3] [4] [5] , as well as in aviremic seronegative family members of HCV-infected subjects 10, 11 . Based on these findings, it has been proposed that repeated subinfectious (low-dose) exposure primes and maintains HCV-specific T cells that confer protective immunity [3] [4] [5] 10, 11 .
We set out to test this hypothesis using chimpanzees that had participated in a study to assess the infectivity of plasma and peripheral blood mononuclear cell (PBMC) samples from patients positive for antibody to HCV who had trace amounts of HCV detected by nested RT-PCR below the detection limit of the standard clinical assay at the NIH (qualitative COBAS Amplicor HCV Test 2.0) 12 . The sporadic reappearance of HCV RNA in these patients coincided with HCVspecific T cell responses and did not result in high-level viremia 12 .
When chimpanzees A3A015 and A3A017 were infused at 9-week intervals with these plasma (infusions 1, 2 and 3) or PBMC (infusion 4) samples (Supplementary Table 1 ), they remained negative for HCV RNA in blood and liver and did not mount antibody responses, but they generated HCV-specific T cell responses, as evidenced by IFN-γ secretion upon in vitro stimulation of PBMCs with HCV peptides (Fig. 1) . A third chimpanzee, A3A020, transiently tested positive for HCV RNA in the blood by nested RT-PCR 10 and 12 weeks after plasma infusion, concomitant with increased HCV-specific T cell responses (Fig. 1) . Such responses were not observed in the control chimpanzee, A3A025, after repeated exposure to blood products from donors who were negative for HCV RNA and antibody to HCV (Fig. 1) . Further characterization of the HCV-exposed chimpanzees revealed that both CD8 + and CD4 + T cells produced IFN-γ, tumor necrosis factor-α (TNF-α) or macrophage inflammatory protein-1β (MIP-1β) in response to multiple HCV antigens ( Supplementary  Fig. 1a−c) , but only a minority were polyfunctional, i.e., secreted multiple cytokines (≤17% CD8 + T cells and ≤12% CD4 + T cells, Supplementary Fig. 1d ). The majority of IFN-γ-producing CD8 + T cells were CD28 − effector (61−88%) or effector memory (12−32%) cells, and none were central memory cells (Supplementary Fig. 1e) .
Chimpanzees that clear an acute HCV infection typically exhibit lower peak viremia levels and faster clearance of a secondary HCV challenge due to the presence of protective memory T cells 8, 9, [13] [14] [15] [16] . However, when the HCV-preexposed chimpanzees (A3A015, A3A017 and A3A020) with HCV-specific T cell responses were challenged with 100 50% chimpanzee infectious doses (CID 50 ) of HCV, they did not control viremia as rapidly as chimpanzee 1605, which had received the same HCV challenge after previous spontaneous clearance of acute Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection Figure 1 Repeated exposure to blood samples from patients positive for antibody to HCV and trace amounts of HCV induces HCV-specific T cell responses. IFN-γ secretion by HCV-specific T cells as determined by cytometric bead array. Vertical arrows indicate the time points at which chimpanzees A3A015, A3A017 and A3A020 were intravenously infused with plasma or PBMCs from patients positive for HCV-specific antibody and trace amounts of HCV and at which chimpanzee A3A025 was infused with blood samples from healthy blood donors negative for HCV-specific antibody and HCV RNA (Supplementary Table 1 
npg l e t t e r S (Fig. 2b ,c for IFN-γ and Supplementary Fig. 2a ,b for TNF-α and MIP-1β), consistent with other recovered and rechallenged chimpanzees 8, 16 . Moreover, ≤2% of the HCV-specific CD8 + T cells from HCV-preexposed chimpanzees were polyfunctional, compared to 42% of those from chimpanzee 1605 (Supplementary Fig. 2c ).
Notably, new T cell responses were significantly suppressed in the three HCV-preexposed chimpanzees, as compared to the peak IFN-γ response of HCV-specific CD8 + and CD4 + T cells in the four control chimpanzees (P < 0.05, Fig. 2b,c and Supplementary Fig. 2d ). This was consistent with suppressed TNF-α + and MIP-1β + responses of HCV-specific T cells (Supplementary Fig. 2a,b) , whereas cytomegalovirus (CMV)-specific T cell responses remained unchanged (Supplementary Fig. 3) .
Suppression of immune responses occurred also in the liver, the site of HCV replication. Because liver biopsies yielded too few lymphocytes for ex vivo analysis, we used quantitative real-time PCR to monitor intrahepatic gene expression. There was almost no increase in the intrahepatic mRNA levels of CD8β, IFN-γ and CXCR3 during the first 6 weeks after HCV challenge in the three HCV-preexposed chimpanzees, whereas they peaked early (week 2) in chimpanzee 1605, consistent with a rapid recall response in this animal (Fig. 3) . The intrahepatic responses of the HCV-preexposed chimpanzees occurred at the same time (weeks 12-14) but with significantly lower magnitude than those of the four control chimpanzees (Fig. 3) . We also observed differences in CXCL11 mRNA levels, but these did not reach statistical significance (P = 0.114, data not shown). Thus, prior exposures to trace amounts of HCV impede HCV-specific recall responses, induction of new T cells and intrahepatic recruitment of CD8 + T cells and IFN-γ production after subsequent HCV challenge.
We next studied suppression by T reg cells as a candidate mechanism for the dampened response in the HCV-preexposed chimpanzees. Whereas the frequency of circulating T reg cells expressing CD4, CD25 and forkhead box P3 (Foxp3) did not differ among chimpanzees at the start of the study (week −42), it increased after repeated exposure to trace amounts of HCV (P < 0.05, week 0, Fig. 4a,b) . This expansion may have been driven by interleukin-2 (IL-2) from HCV-specific effector T cells (Fig. 4c) , as T reg cells require exogenous IL-2 for their maintenance and proliferation 18 . Challenge with 100 CID 50 HCV further increased the T reg cell frequency in the three HCV-preexposed chimpanzees as compared to the previously HCVrecovered chimpanzee 1605 (Fig. 4a) and the four control chimpanzees (P = 0.0002, repeated-measures analysis of variance (ANOVA), Fig. 4b) . Furthermore, the T reg cell subset composition changed with an expansion of CD38 + activated, CD39 + functional 19 and CD27 − CD197 − CD45RA − effector 20 T reg cells (Fig. 4d) .
The three HCV-preexposed chimpanzees also displayed a higher intrahepatic T reg frequency (Fig. 4e) and higher peak intrahepatic Foxp3, IL-10 (P < 0.05, respectively) and TGF-β (P = 0.058) mRNA levels than chimpanzee 1605 and the four control chimpanzees after HCV challenge (Fig. 4f) . In vitro depletion of T reg cells from PBMCs at 8 weeks and 19−37 weeks after HCV challenge enhanced HCV-specific T cell responses by a greater percentage in the HCVpreexposed chimpanzees than in the control chimpanzees (P < 0.05, Fig. 4g,h ) with preserved immune hierarchy (Supplementary Fig. 4a ). As IL-10 secreted by T reg cells can directly suppress antigen-specific T cell responses, we confirmed the suppressive function of T reg cells by in vitro IL-10 neutralization combined with IL-10 receptor blockade, which significantly enhanced HCV-specific T cell responses from HCV-preexposed but not control chimpanzees (P < 0.05, Fig. 4i and Supplementary Fig. 4b ). The three HCV-preexposed chimpanzees also displayed a higher frequency of B7-H4 + circulating macrophages and higher intrahepatic B7-H4 mRNA levels than the four control chimpanzees after HCV challenge (Supplementary Fig. 5 ). T reg cells have been shown to suppress effector T cell responses by IL-10-mediated upregulation of B7-H4 on antigen-presenting cells 21, 22 , and the timing of the intrahepatic B7-H4 mRNA peak coincided with the absence of HCV-specific T cell responses 8−12 weeks after HCV challenge in the HCV-exposed chimpanzees. The control chimpanzees mounted strong T cell responses at that time (Fig. 2b,c) . These results suggest that HCV-specific T cells were induced after HCV challenge in all chimpanzees but functionally suppressed in the HCV-preexposed chimpanzees. Of note, the sole HCV-preexposed chimpanzee that cleared the challenge inoculum (A3A020) did so after a decrease in T reg cell frequency (Fig. 4a) and a concomitant increase in HCV-specific CD8 + and CD4 + T cells between weeks 10 and 16 (Fig. 2b,c) .
In summary, we demonstrate that T cells primed by trace amounts of HCV do not generate effective recall responses upon subsequent HCV infection. Furthermore, exposure to trace amounts of HCV predisposes to T reg cell expansion, which suppresses HCV-specific effector T cells during subsequent acute infection. This scenario differs Peak CXCR3 mRNA Figure 3 Repeated exposure to blood samples from patients positive for antibody to HCV and trace amounts of HCV suppresses intrahepatic T cell recruitment and IFN-γ production upon subsequent HCV challenge.
(a-c) Intrahepatic CD8β (a), IFN-γ (b) and CXCR3 (c) mRNA levels as determined by RT-PCR, normalized to endogenous references (GAPDH and β7) and expressed as relative increase over week 0 expression, which was set to a value of 1. For chimpanzees 98A005, 97A009, 97A015 and 1605, the increase in CD8β and IFN-γ mRNA levels was calculated from previously reported data 40 . The vertical arrows indicate the time point (week 0) at which all chimpanzees were challenged with 100 CID 50 HCV genotype 1a. Right graphs represent the peak mRNA levels during acute HCV infection for each chimpanzee. The horizontal lines indicate the median. P values were calculated with the Mann-Whitney U-test.
npg l e t t e r S nature medicine VOLUME 19 | NUMBER 12 | DECEMBER 2013 1 6 4 1 from allergen desensitization, where exposure to increasing allergen doses suppresses IL-4 and IL-5 production through T reg cell induction and, contrary to our findings, increases IFN-γ responses 23 . Likewise, it differs from IL-10-dependent immunotolerance in beekeepers, which is induced by repeated high-dose antigen exposure 24 . The absence of substantial inflammation after subinfectious exposure to HCV may be key to the observed T reg cell induction, as suggested by the increased expression of Foxp3 in CD4 + T cells in mice that received small amounts of peptide 25 without adjuvants 25, 26 . Here, we demonstrate that similar effects can be achieved with very small doses of live virus rather than inert antigen. A possible lack of signal 2 (co-stimulation) or, without sufficient viral replication, signal 3 (type I IFN) may impede the induction of optimal effector CD8 + T cells 27 and instead favor T reg cell induction. The accelerated T reg cell expansion in the presence of high antigen levels after HCV challenge may imply HCV specificity, as suggested by in vitro studies 28, 29 . IL-2 consumption by the expanding T reg cell population 18 after HCV challenge may suppress new effector T cells, which depend on prolonged IL-2 signals 30, 31 .
Our results were generated in the in vivo model that most closely represents HCV infection in humans, and they warrant confirmation in human populations. At present, limited data are available to distinguish between subinfectious and full-dose HCV exposure in humans. Published studies on T cell responses in HCV RNA-negative and seronegative individuals are of cross-sectional design 2-5,10,11 and thus do not exclude the possibility that T cell responses resulted from past acute HCV infection with systemic viremia and subsequent antibody loss 32 . However, we have recently shown in a prospective study that subinfectious HCV exposure of healthcare workers through accidental needlestick can indeed induce HCV-specific T cell responses in the absence of quantifiable viremia and HCV-specific antibodies 33 . Based on this study in humans and the HCV challenge data in the nonhuman primate model, we refute the notion that individuals frequently exposed to subinfectious HCV who remain negative for antibody to HCV may have T cell-mediated protective immunity upon HCV infection 3, 5, 10, 11 . We propose that T cell-based protective immunity, as described in rechallenged chimpanzees 8 and suggested in some re-infected injection drug users 34, 35 , requires clearance of a previous acute infection with systemic viremia.
The number of experimental chimpanzees in this study was too small to allow a statistical comparison of the outcome of HCV challenge in HCV-preexposed and naive chimpanzees. However, it is npg l e t t e r S conceivable that the observed T reg cell-mediated immune suppression also occurs in individuals who live in endemic areas, rendering them less resistant upon subsequent HCV infection than individuals in nonendemic areas. This may extend to T cell responses to other endemic pathogens and would be consistent with the finding that the percentage and the number of T reg cells are higher among healthy individuals in a rural village with seasonal malaria than among individuals in an urban area where malaria is rare 36 . Our findings may be relevant for vaccine research and for epidemiological studies because an increased T reg cell frequency reduces the response to vaccines 37 . They may, for example, offer a potential explanation for geographical variation in the efficacy of Mycobacterium bovis bacillus Calmette-Guérin vaccination against tuberculosis, which is less effective in endemic areas 38 . Along this line, it would be of interest to examine whether an increased T reg cell frequency in HIV-negative individuals in HIV-endemic areas may have contributed to the vaccine failure in the HIV STEP study 39 . Considering that in vitro T reg cell depletion restored the suppressed HCV-specific T cell responses in our study, strategies for in vivo blockade of these suppressive mechanisms may facilitate the development of T cell-based vaccines against endemic pathogens such as HCV, HIV, Mycobacterium tuberculosis and Plasmodium species.
MeTHodS
Methods and any associated references are available in the online version of the paper. 
oNLINe MeTHodS
Chimpanzees. Chimpanzees A3A015, A3A017, A3A020 and A3A025 were studied at New Iberia Research Center (NIRC), New Iberia, LA under protocols approved by the University of Louisiana Lafayette Animal Care and Use Committee (ACUC). Chimpanzees A3A015, A3A017 and A3A020 were intravenously infused with 17-31 ml plasma from patients positive for antibody to HCV who, after completion of interferon-based therapy, had tested negative for HCV RNA by qualitative COBAS Amplicor HCV Test 2.0 (Roche) but positive by nested RT-PCR 12 . Chimpanzees A3A015 and A3A017 were subsequently infused at 9-week intervals with two additional plasma samples and one PBMC sample (3.5 × 10 7 ) from additional patients with trace amounts of HCV RNA. The study was conducted to assess whether these samples were infectious. The control chimpanzee A3A025 was infused, at the same time intervals, with plasma and PBMCs from blood donors without past HCV infection (Supplementary Table 1) . Subjects gave informed consent and were studied under protocols approved by the NIDDK Institutional Review Board.
Fifteen weeks (for A3A015, A3A017 and A3A025) and 26 weeks (for A3A020) after the final infusion, all chimpanzees were challenged with 100 CID 50 HCV genotype 1a. At the indicated study time points, serum was isolated and cryopreserved on site. Acid citrate dextrose-anticoagulated blood samples, a liver biopsy piece in RPMI1640 with 5% FBS and a snap-frozen liver biopsy piece were shipped overnight to NIH. PBMCs and liver-infiltrating lymphocytes were isolated as described 41 .
Cryopreserved PBMCs, serum and liver biopsies from (i) chimpanzees 98A005, 97A009 and 97A015, which had been challenged with 100 CID 50 HCV genotype 1a in a previous study at NIRC 17 , and (ii) chimpanzee 1605, which had resolved an acute HCV infection before challenge with 100 CID 50 HCV genotype 1a at the Food and Drug Administration (FDA), Rockville, Maryland, in a previous study 14 , were studied for comparison (Supplementary Table 1) under protocols approved by the University of Louisiana Lafayette ACUC and the FDA ACUC, respectively.
Multicolor flow cytometry. Analysis of HCV-specific T cell responses by cytometric bead array.
Fresh PBMCs (2 × 10 5 per well) were stimulated in RPMI1640 containing 5% FBS, 100 IU ml −1 penicillin, 100 µg ml −1 streptomycin and 2 mM l-glutamine (Mediatech) with 18 pools of overlapping 15-mer HCV genotype 1a (H77) peptides of the identical sequence as the challenge virus (1 µg ml −1 per peptide, 600 peptides total) 12 or DMSO in 96-well plates. Culture supernatants were harvested after 42 h to quantitate IFN-γ, TNF-α, MIP-1β and IL-2 by cytometric bead array (BD Biosciences). The HCV-specific response to each peptide pool was calculated by subtracting the background response (DMSO) from the response to each individual peptide pool. Cumulative responses to structural and nonstructural HCV antigens are shown (Fig. 1) .
Analysis of HCV-specific T cell responses by intracellular cytokine staining. Cryopreserved and thawed PBMCs (2 × 10 6 per tube) were stimulated with or without six pools of 15-mer HCV genotype 1a peptides with an 11-amino-acid overlap that spanned the HCV NS3, NS4, NS5A and NS5B sequences (4 µg ml −1 per peptide). Antibodies to CD28 at 1 µg ml −1 (clone CD28.2, BD Biosciences) and CD49d at 1 µg ml −1 (clone 9F10, BD Biosciences) were included in the peptide stimulation. After 1 h incubation at 37 °C and 5% CO 2 , 10 µg ml −1 brefeldin A (Sigma-Aldrich) was added. After 12 h incubation, the cells were stained with Alexa Fluor 700-conjugated antibody to CD3 (clone UCHT1, 1:100) allophycocyanin-H7-conjugated antibody to CD8 (clone RPA-T8, 1:33) and Brilliant Violet 421-conjugated antibody to CD4 (clone RPA-T4, 1:33) from BD Biosciences for 30 min at 4 °C, washed, fixed, permeabilized using FACS Perm 2 buffer (BD Biosciences) and stained with FITC-conjugated antibody to IFN-γ (clone 1-D1K, 1:33, Mabtech), allophycocyanin-conjugated antibody to TNF-α (clone MAb11, 1:20, BioLegend) and phycoerythrin-Cy7-conjugated antibody to MIP-1β (clone D21-1351, 1:20, BD Biosciences) for 30 min at room temperature. After two washes, a minimum of 30,000 CD8 + CD3 + T cell-gated events were acquired (Supplementary Fig. 6a ). Data were expressed as number of cytokine-secreting CD3 + CD8 + or CD3 + CD4 + cells per 10 6 lymphocytes to allow comparison with published studies. The HCV-specific response to each pool was calculated by subtracting the background response (in the absence of HCV peptides) from the response to each individual peptide pool.
